OTCPicks.com

FEATURED COMPANY

WIND ENERGY AMERICA INCORPORATED (OTCBB: WNEA)
"Up 10.71% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/WNEA.php

Company Profile:
www.otcpicks.com/wind-energy-america/wind-energy-america-2.htm

Wind Energy America Inc. develops and operates wind energy projects in the Great Plains and the Midwest, regions known for their high quality wind energy resources. The Company owns interests in three wind farms: Shaokatan Hills LLC, Lakota Ridge LLC and CHI Energy. At present, WNEA owns a developer's stake and a minimal interest producing negligible cash flow in these wind farms. Over the next two years the developer’s stake will begin producing significant cash flow from these projects. The three wind farms together contain 79 modern wind turbines and have a total rated capacity of 53.5 megawatts (MW). They are collectively generating approximately 160 million kilowatt hours (kWh) of electricity annually. In addition to these properties, the Company owns a 3 percent equity interest in Averill Wind LLC, a 10 MW wind farm being developed near Fargo, N.D., another region favorable for wind power energy.

WNEA News:

November 19 - Wind Energy America Inc. Obtains Financing to Complete Minnesota Wind Farm

Wind Energy America Inc. (OTCBB: WNEA) announced that it has started ordering parts and commencing construction and interconnect operations to complete its wind farm project in Minnesota which contains two of the Gamesa wind turbines acquired in the Boreal Energy asset purchase. When commissioning of these two turbines is completed, WNEA will receive its first material revenues from generating utility-scale electricity from wind power. This Buffalo Ridge wind farm and its revenue production will be 100% owned by WNEA.

Financing for this wind farm project was obtained from a California holding company through a sale/leaseback of our Midwest Energy Center facility in Lincoln County MN. WNEA received net proceeds of approximately $l,400,000 from this sale/leaseback transaction. We also have the option after 2 years to repurchase the facility at a price which represents a small percentage increase over the initial sale/leaseback price.

Robert Knutson, managing director of WNEA and the person responsible for obtaining and closing this significant funding, stated: “Given the current difficulties of raising development capital due to the recent collapse of worldwide equity markets, we are pleased that WNEA has been able to obtain critical funding at this time. These proceeds have enabled us to satisfy substantial overdue bank debt secured by the project, pay for interconnect and other costs owed to the utility which will purchase electricity generated by the project, acquire the necessary transformer equipment and other wind turbine parts and materials, and retain an experienced wind power contractor to complete the project for us.”

FEATURED COMPANY

NEXIA HOLDINGS INCORPORATED (OTCBB: NXHD)

Detailed Quote: http://www.otcpicks.com/quotes/NXHD.php

Company Profile:
http://www.otcpicks.com/nexia-holdings/nexia-holdings.htm

Nexia Holdings, Inc., headquartered in Salt Lake City, Utah, is a diversified holdings company with operations in real estate, health & beauty, and fashion retail. Nexia owns a majority interest in Landis Lifestyle Salon (www.landissalons.com), a hair salon built around the world-class Aveda™ product line. Through its Style Perfect, Inc. subsidiary, Nexia owns the innovative retail and design firm Black Chandelier and its related brands. Black Chandelier currently operates one retail location and online store at www.blackchandelier.com.

NXHD News:

December 22 - Nexia Outlines Marketing Efforts

Nexia Holdings, Inc. (OTCBB: NXHD) (OTC: GRNE) announced that management is both reviewing and planning for its advertising and marketing efforts in 2009. CEO Richard Surber stated that, "I first want our shareholders, employees, and customers to be aware of some of the unique and traditional marketing efforts that have occurred over 2008 and how we plan to improve upon those efforts in 2009."

The following is a list of traditional media which include magazines, newspapers, mailers, radio, email, press releases, and other means that we have used or been featured in during 2008:

* Salt Lake Tribune with a weekly readership of approximately 900,000 which we recently ran a half page ad this last weekend.

* Salt Lake Magazine is a high end magazine distributed throughout the Salt Lake Valley.

* IN Utah This Week is a weekly newspaper that features our companies on a weekly basis to the hipster crowd and has a circulation of about 40,000.

* Yellow Pages.

* Hometown Values is a discount mailer to thousands of households in the Salt Lake Valley.

* American Salon Magazine has ranked Landis Lifestyle Salon as the #1 salon in Utah.

* Utah Business Magazine has ranked Nexia as the 33rd largest public company in Utah based upon 2007 revenues.

* DEX Yellow Pages.

* Verizon Yellow Pages.

* M6 Marketing is a text messaging service; we recently signed a 12 month contract with them.

* KCPW Radio is the local station for National Public Radio. Nexia is a proud supporter of this station.

"Our biggest and most effective way to get the word out on our salon products and services is word of mouth at the local level coupled with throwing events to show our appreciation for our clients. I am cultivating my success into our New Artist Stylists," noted Logan Fast, Master Stylist at Landis Salons and newly appointed Vice President of Green Endeavors Ltd. (OTC: GRNE).

Fast continued, "In 2009, I will release more specifics on who we will be advertising with and how Nexia can generate further interest in its products and services. In addition to traditional marketing, I hope to be able to lay out how we intend to better inform the investment community about Nexia, this will focus heavily on our web presence.

"A critical element to Nexia's success will be to make sure that Nexia's marketing dollars continue to be well spent. I look forward to 2009 when our agreement with Clearvision International, Inc. kicks in with an estimated value of about $2M in media which should include celebrity endorsements, billboards, TV, radio, and more."

FEATURED COMPANY

GREENCHEK TECHNOLOGY INCORPORATED (OTCBB: GCHK)

Detailed Quote: http://www.otcpicks.com/quotes/GCHK.php

Company Profile:
www.otcpicks.com/greenchek-technology/greenchek-technology.htm

GreenChek Technology, Inc. manufactures and distributes hydrogen injection technology devices that primarily focus on mobile transportation applications and industrial generative power applications. It also provides mobile greenhouse gas emissions reduction technology. The company's Onboard Hydrogen Generation and Injection technology is used for emissions reduction technology and fuel economy enhancement in trucks, locomotives, and automobile engines. It has operations in the United States, Canada, Asia, and Europe. The company, formerly known as Ridgestone Resources, Inc., was founded in 2006 and is headquartered in San Francisco, California.

GCHK News:

November 13 - GreenChek Signs Strategic European Distribution Agreement

GreenChek Technology Inc. (OTCBB: GCHK), a leading globally focused provider of hydrogen based technology for mobile transportation and stationary power generation applications, reported today that they have signed a strategic European distribution agreement with Technical Environmental Solutions Europe Ltd. (TESEL). TESEL is a world-class and world-renowned distribution Company focused in Europe. The November 4, 2008, announcement of the Letter of Intent has been finalized by both parties.

GreenChek manufactures an emission reducing device simply known as the ERD 1.0, which can be retrofitted to any vehicle or combustible engine regardless of fuel source. This device reduces vehicle emissions as well as increases fuel economy.

GreenChek’s Chief Strategy Officer, Donald Walling, stated, “We are very pleased to have signed this agreement with TESEL. Our proven ERD addresses the specific needs of multiple verticals in the European transportation industry. The agreement with TESEL marks a major milestone on route to our plan for aggressive global distribution of the ERD unit.” Walling added, “Our partnership with TESEL gives us the knowledge and ability to address and navigate complex European Government and intricate European transportation industry needs.”

FEATURED COMPANY

COPPER KING MINING CORPORATION (OTC: CPRK)

Detailed Quote: http://www.otcpicks.com/quotes/CPRK.php

Company Profile:
http://www.otcpicks.com/copper-king-mining/copper-king-mining.htm

Copper King Mining Corporation currently owns approximately 1200 acres in the Drum Mountains of Utah, which are patent deeded mining claims which contain gold, silver and copper. The company recently added to its holdings by filing six more claims on land which was inside their holdings, but not patent deeded. Contiguous to that acreage is approximately 1100 acres of claims filed by Western Utah Copper Company. As the companies explored the concept of a joint venture on the Drum Mountain properties, it was decided that a very viable consideration was to join the total assets of both companies.

CPRK News:

December 24 - Copper King Announces Compliance with Nevada Star Option and Agreement

Copper King Mining Corporation (OTC: CPRK) announced that its subsidiary, Western Utah Copper Company (WUCC), has fully complied with the Nevada Star Option and Agreement (the Option Agreement), by commencing production in full satisfaction with the requirements of the Option Agreement.

Mr. Monty Moore, former president and CEO of Nevada Star at the time of the Option Agreement’s execution, in an private interview said, " WUCC has overcome nearly insurmountable odds and obstacles, such as no commercial power, in order to comply with both the spirit and the letter of the Option Agreement as written and agreed to at the time."

As Nevada Star’s presiding officer at the time, Moore said, “WUCC has more than accomplished that which was agreed upon. The intent of the Option Agreement was that the properties be moved forward into production. In spite of periods of force majeure, properly excused by the Option Agreement, and even though substantial additional time still remains for WUCC to complete of the Option Agreement requirements as a result of the occurrence, recurrence and the extent of force majeure conditions, WUCC has steadily progressed in moving the project into production and fulfilling the requirements to complete the Option Agreement. Now, WUCC has constructed and is placing in operation a mill at a cost in excess of $50 million, and it certainly is apparent that completion of the Option Agreement requirements has been more than accomplished.”

FEATURED COMPANY

SPONGETECH DELIVERY SYSTEMS (OTCBB: SPNG)

Detailed Quote: http://www.otcpicks.com/quotes/SPNG.php

Company Profile: http://www.otcpicks.com/spongetech/spongetech.htm

SpongeTech Delivery Systems is a development stage company which designs, produces, markets and distributes cleaning products for vehicular use utilizing patented technology relating to sponges containing hydrophilic (liquid absorbing) foam polyurethane matrices. The Company's sponges are specially configured with an outer contact layer and an inner matrix, which is loaded with specially formulated soaps and wax that are released when the sponge is applied to a surface with minimal pressure. The Company's products are currently designed specifically for vehicular cleaning use. However, the Company is exploring the possibility of using its patented technology for the development of sponges for other uses, including for use with anti-bacterial, bath and kitchen soaps for household uses, as well as for use as a children's bath foam sponge.

SPNG News:

December 18 - SpongeTech® Delivery Systems, Inc. Announces Top 20 Ranking on Jordan Whitney 'Greensheet' Report

SpongeTech Delivery Systems, Inc. (OTCBB: SPNG), “America's Cleaning Company™,” announced that, for the week ending December 10, 2008, its product reached No. 19 on the Jordan Whitney Top 60 Direct Response Spots for the same week. This report ranks the top sixty direct response spots which sell traditional Direct Response Television ("DRTV") products directly or indirectly (excluding music offers) based upon confidential media budgets and Jordan Whitney's monitoring of national cable and selected broadcast markets. Jordan Whitney, an independent clearinghouse, is one of the industry's oldest monitoring services that provide up-to-date information on DRTV, which include infomercials, short-form DRTV commercials, the websites for these products, and the companies involved in their production and distribution. Jordan Whitney also monitors media budgets for companies that utilize cable and broadcast direct response marketing television.

SpongeTech also reached the No. 12 spot on the Jordan Whitney Top 20 Short-Form Retail Products Report, which ranks the top 20 traditional short-form products using DRTV commercials that are two minutes or less in length.

SpongeTech's COO Steven Moskowitz stated, "These high rankings confirm that our efforts via TV, radio, and web are effectively finding our target consumers, and we will continue to be aggressive in our development of new commercials and spots to introduce our cutting-edge delivery system products throughout America and internationally in 2009."

SpongeTech® Delivery Systems, Inc. CEO Interviewed Live on Steve Crowley's American Scene Radio Show

SpongeTech's CEO Interview Aired Today on American Scene Radio Show

SpongeTech Delivery Systems, Inc. (OTCBB: SPNG), “America's Cleaning Company™,” announced that its CEO and President, Michael Metter, will be interviewed Dec. 18 on Steve Crowley's American Scene Radio Show at 9:24 a.m. EST. The interview can be heard live on BusinessTalkRadioNetwork® affiliate radio stations streamed on its website (www.businesstalkradio.net). You can find local radio stations by accessing the website, as well. Mr. Metter will be scheduled for future interviews on American Scene, where he will keep listeners updated on SpongeTech®'s products and developments.

FEATURED COMPANY

SOMATIC SYSTEMS INCORPORATED (OTC: SMAS)

Detailed Quote: http://www.otcpicks.com/quotes/SMAS.php

Company Profile:
http://www.otcpicks.com/somatic-systems/somatic-systems.htm

Somatic Systems is the worldwide center for Clinical Somatics™, the groundbreaking drug-free, non-surgical approach to pain relief. This proprietary system uses natural, non-invasive movement techniques — conducted through one-hour hands-on sessions, therapeutic exercises classes, and home exercises lasting as little as 5 minutes a day — to relieve pain and limitation resulting from accident, trauma and repetitive stress, including back pain, knee pain, joint problems, carpal tunnel syndrome, TMJ, scoliosis, bursitis, sciatica, headaches, tendonitis and more. Clinical Somatics™ also provides performance gains and injury prevention for casual and professional athletes. Somatic Systems is pursuing a 3-part growth strategy, consisting of a nationwide rollout of pain management Somatics Clinics; increased production and distribution of therapeutic videos, books, and other retail self-help Somatics Products; and expanded Somatics Training Programs to supply Clinic practitioners serving medical and orthopedic professionals and institutional and corporate programs. The company operates a suite of web sites offering Somatics information, products, resources and opportunities at www.somatics.org.

SMAS News:

December 17 - Somatic Systems, Inc. CEO Interviewed Live Thursday on Investment Nation

Somatic Systems, Inc. (OTC: SMAS) CEO Steven Aronstein will be featured tomorrow in an exclusive interview on Investment Nation (www.investmentnation.com). The live interview will be held and audio broadcast in the website's chatroom at 6:00 PM Eastern Time.

Shareholders should go to www.investmentnation.com and search for Somatic Systems to find the company's forum page and post their interview questions on the site in advance. Participants will also be able to ask questions at the time of the conference.

Earlier this month, it was announced that the Investment Nation website would begin featuring monthly interviews with Somatic Systems' CEO based on shareholder questions, to keep shareholders updated with the company's latest plans and to get timely answers to their pressing questions. Somatic Systems has stated it is always seeking more ways to communicate with shareholders and maintain transparency, and the company sees the Investor Nation monthly interviews as an exciting opportunity to expand this conversation.

Investment Nation provides an online forum for shareholders and other investors to share facts, due diligence and investment ideas about the Somatic Systems. Investment Nation was built to provide a forum for new and experienced investors to gather and share market information in a clean and professional environment. The site is designed to be user-friendly and simple, allowing investors to get the market information they need quickly and easily. Everything about the site was put together based on investors needs. Investment Nation limits both the stock pumping and bashing found on other investment forums along with cracking down on paid bashers and stock promoters.

Somatic Systems has been involved with numerous high profile activities recently, including becoming registered as a US government contractor, meetings with the US military to become a fully approved health care service, and dramatically increased media coverage including current national and international television appearances on MoneyTV — a financial industry talk show airing last week to greater than 100 million households — and Health Forum — a syndicated health feature airing 50 times including on the WE tv network this morning to over 70 million households. The Investment Nation feature interviews are a timely opportunity to follow Somatic Systems during this exciting time for the company.

STOCKS TO WATCH

GENTA INCORPORATED (OTCBB: GNTA)
"Up 64.86% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/GNTA.php

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company’s research platform: DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta’s Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a “named-patient” basis in countries outside the United States.

GNTA News:

January 5 - Genta Summarizes Phase 2 Activity and Receives Orphan Drug Designation in Gastric Cancer for Tesetaxel, a Leading Oral Taxane in Clinical Development

Genta Incorporated (OTCBB: GNTA) announced that the Company has received notice from the U.S. Food and Drug Administration (FDA) that tesetaxel, the latest addition to Genta’s oncology product portfolio, has been granted designation as an “Orphan Drug” for treatment of patients with advanced gastric cancer. Orphan drug status provides for a period of marketing exclusivity, certain tax benefits, and an exemption from certain fees upon submission of a New Drug Application. As a late Phase 2 agent, the Company believes tesetaxel is the leading oral taxane currently in clinical development.

In the completed Phase 2 study, 35 patients with advanced gastric cancer were treated with tesetaxel at doses ranging from 27 to 35 mg/m2 once every three weeks. All patients had received extensive prior treatment, having failed a combination regimen that included cisplatin plus 5-fluorouracil or Xeloda®, and all but 2 patients had received a third chemotherapy drug with this regimen. Final intent-to-treat analysis, including all patients enrolled in the study, showed that 5 patients achieved a partial response, 2 patients achieved a partial response unconfirmed by CT scan, and 14 patients achieved stable disease, for an overall major response rate of 20% and a disease-control rate of 60%. The most serious adverse reaction was Grade 3-4 neutropenia, which occurred in 57% of patients. Six patients failed to complete the first course of treatment. Five patients died on study from differing causes that included intestinal perforation, pneumonia, hepatic failure, hemorrhagic shock, and rapid disease progression. One patient withdrew before receiving the first treatment dose.

“These response data for tesetaxel in a critically ill patient population show clinical activity at levels that are at least comparable to studies with other taxanes,” said Dr. Raymond P. Warrell, Jr., Genta’s Chief Executive Officer. “Based on these data, we have consulted extensively with international experts and will be defining a global registration path for tesetaxel as a 2nd-line treatment for patients with advanced gastric cancer. FDA designation as an Orphan Drug provides important assistance in the clinical development process.”

ABOUT TESETAXEL

Tesetaxel is a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. However, both prototype agents suffer from serious safety issues, particularly hypersensitivity reactions related to intravenous infusions that are occasionally fatal and that require careful premedication and observation. Other prominent side-effects of this drug class include myelosuppression (low blood counts) and peripheral neuropathy (disabling nerve damage).

With administration as an oral capsule, tesetaxel was developed to maintain the high antitumor activity of the taxane drug class while eliminating infusion reactions, reducing neuropathy, and increasing patient convenience. The oral route also enables development of novel schedules that may expand dosing options when tesetaxel is used alone or in combination with other anticancer drugs. Preclinically, tesetaxel has demonstrated substantially higher activity against cell lines that were resistant to paclitaxel and docetaxel, since acquired resistance is not mediated by the multidrug-resistant p-glycoprotein.

As a late Phase 2 oncology product, tesetaxel has demonstrated anticancer activity in its initial clinical trials, and the drug has not been associated with the severe infusion reactions that are linked with other taxanes. Moreover, unlike other oral taxanes, nerve damage has not been a prominent side effect of tesetaxel. Thus, the drug offers substantial opportunities to improve patient convenience, safety, and anticancer activity. More than 250 patients worldwide have been treated with oral tesetaxel in Phase 1 and Phase 2 clinical trials.

DOR BIOPHARMA INCORPORATED (OTCBB: DORB)
"Up 63.33% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/DORB.php

DOR BioPharma, Inc. (DOR) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of hematopoietic cell transplantation. DOR expects to begin a confirmatory Phase 3 clinical trial of orBec® for the treatment of GI GVHD in 1H 2009. orBec® is also currently the subject of an NIH-supported, Phase 2, randomized, double-blind, placebo-controlled trial in the prevention of acute GVHD. Oral BDP may also have application in treating other gastrointestinal disorders characterized by severe inflammation. Additionally, DOR has a Lipid Polymer Micelle (LPM(TM)) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis. Through its Biodefense Division, DOR is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. DOR's biodefense products in development are recombinant subunit vaccines designed to protect against the lethal effects of exposure to ricin toxin, botulinum toxin and anthrax. DOR's ricin toxin vaccine, RiVax™, has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers.

DORB News:

January 5 - DOR BioPharma Receives SPA Clearance From the FDA to Begin Confirmatory Phase 3 Clinical Trial of orBec® in GI GVHD

DOR BioPharma, Inc. (OTCBB: DORB) (DOR or the Company) announced that it has reached agreement with the US Food and Drug Administration (FDA) on the design of a confirmatory, pivotal Phase 3 clinical trial evaluating its lead product orBec® for the treatment of acute gastrointestinal Graft-versus-Host Disease (GI GVHD). The agreement was made under the FDA's Special Protocol Assessment (SPA) procedure.

An agreement via the SPA procedure is an agreement with the FDA that a Phase 3 clinical trial's design (e.g., endpoints, sample size, control group and statistical analyses) is acceptable to support a regulatory submission seeking new drug approval. After the study begins, the FDA can only change a SPA for very limited reasons.

Based on data from the prior Phase 3 study of orBec®, the upcoming confirmatory Phase 3 protocol will be a highly powered, double-blind, randomized, placebo-controlled, multi-center trial and will seek to enroll an estimated 166 patients. The primary endpoint is the treatment failure rate at Study Day 80. This endpoint was successfully measured as a secondary endpoint (p-value = 0.005) in the previous Phase 3 study as a key measure of durability following a 50-day course of treatment with orBec® (i.e., 30 days following cessation of treatment).

"We are very pleased to gain SPA agreement with the FDA on our confirmatory, pivotal Phase 3 study," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of DOR. "The depth and strength of our available Phase 3 data have allowed us to design and power this pivotal trial that we believe maximizes orBec®'s chances for success. With our primary endpoint of the 'treatment failure rate at Study Day 80,' we expect to replicate statistical significance in this clinically meaningful endpoint with orBec®. We expect to initiate this trial in the first half of 2009."

Dr. Schaber continued, "With the regulatory clarity received from FDA, we are now confident that we have a more clearly defined development path that has the potential to lead to regulatory approval of orBec®. We are excited to move forward with this trial in an effort to address the significant unmet medical need of GI GVHD."

ABOUT ORBEC®

Two prior randomized, double-blind, placebo-controlled Phase 2 and 3 clinical trials support orBec's® ability to provide clinically meaningful outcomes when compared with the current standard of care, including a lowered exposure to systemic corticosteroids following allogeneic transplantation. Currently, there are no approved products to treat GI GVHD. The first trial was a 60-patient Phase 2 single-center clinical trial conducted at the Fred Hutchinson Cancer Research Center. The second trial was a 129-patient pivotal Phase 3 multi-center clinical trial of orBec® conducted at 16 leading bone marrow/stem cell transplantation centers in the US and France. Although orBec® did not achieve statistical significance in the primary endpoint of its pivotal trial, namely median time-to-treatment failure through Day 50 (p-value 0.1177), orBec® did achieve statistical significance in other key secondary endpoints such as the proportion of patients free of GVHD at Day 50 (p-value 0.05) and Day 80 (p-value 0.005) and the median time to treatment failure through Day 80 (p-value 0.0226), as well as a 66% reduction in mortality among patients randomized to orBec® at 200 days post-transplant with only 5 patient (8%) deaths in the orBec® group compared to 16 patient (24%) deaths in the placebo group (p-value 0.0139). At one year post randomization in the pivotal Phase 3 trial, 18 patients (29%) in the orBec® group and 28 patients (42%) in the placebo group died within one year of randomization (46% reduction in mortality, hazard ratio 0.54, 95% CI: 0.30, 0.99, p=0.04, stratified log-rank test).

In the Phase 2 study, the primary endpoint was the clinically relevant determination of whether GI GVHD patients at Day 30 (the end of treatment) had a durable GVHD treatment response as measured by whether or not they were able to consume at least 70% of their estimated caloric requirement. The GVHD treatment response at Day 30 was 22 of 31 (71%) vs. 12 of 29 (41%) in the orBec® and placebo groups, respectively (p-value 0.02). Additionally, the GVHD treatment response at Day 40 (10 days post cessation of therapy) was 16 of 31 (52%) vs. 5 of 29 (17%) in the orBec® and placebo groups, respectively (p-value 0.007).

orBec® represents a first-of-its-kind oral, locally acting therapy tailored to treat the gastrointestinal manifestation of GVHD, the organ system where GVHD is most frequently encountered and highly problematic. orBec® is intended to reduce the need for systemic immunosuppressive drugs to treat GI GVHD. Beclomethasone dipropionate (BDP) is a highly potent, topically active corticosteroid that has a local effect on inflamed tissue. BDP has been marketed in the US and worldwide since the early 1970s as the active pharmaceutical ingredient in a nasal spray and in a metered-dose inhaler for the treatment of patients with allergic rhinitis and asthma. orBec® is formulated for oral administration as a single product consisting of two tablets; one tablet is intended to release BDP in the proximal portions of the GI tract, and the other tablet is intended to release BDP in the distal portions of the GI tract.

In addition to issued patents and pending worldwide patent applications held by or exclusively licensed to DOR, orBec® also benefits from orphan drug designations in the US and in Europe for the treatment of GI GVHD, which provide for seven and 10 years of post-approval market exclusivity, respectively.

ABOUT GI GVHD

GI GVHD is a debilitating and painful disease and constitutes an unmet medical need. It is a common disorder among immunocompromised cancer patients after receiving hematopoietic cell transplantation. Unlike organ transplants where the patient's body may reject the organ, in GVHD it is the donor cells that begin to attack the patient's (host's) body — most frequently the gastrointestinal tract, liver and skin. Patients with mild-to-moderate GI GVHD typically develop symptoms of anorexia, nausea, vomiting and diarrhea. If left untreated, GI GVHD can progress to ulcerations in the lining of the GI tract, and in its most severe form, can be fatal.

SOLAR POWER INCORPORATED (OTCBB: SOPW)
"Up 58.33% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/SOPW.php

Founded in 2005, Solar Power, Inc. is a vertically integrated solar energy solution provider offering the North American residential, commercial and public sector building markets a complete solution through a single brand. With a state of the art manufacturing facility in Shenzhen, China, Solar Power, Inc. provides turnkey design-build solutions through its Roseville, California headquarters and a growing retail distribution network.

SOPW News:

January 5 - Solar Power, Inc. and JA Solar to Enter Agreement for up to 60 Megawatts of Cells in 2009

JA Solar Commits to Sell up to 60 Megawatts of Polycrystalline Photovoltaic Cells to Solar Power, Inc. to Meet Growing Demand for Its Modules and Systems

Solar Power, Inc. (OTCBB: SOPW) (“SPI”) has entered into a one-year supply agreement with JA Solar Holding Co., Ltd. (“JA Solar”) (Nasdaq: JASO). JA Solar has committed to supply up to 60 megawatts of its 6” polycrystalline photovoltaic (“PV”) cells based on monthly requirements from SPI. Based in Hebei, China, JA Solar is one of the world’s top producers of high-performance solar cells. The cells will be used for the ongoing production of SPI’s solar modules and to meet growing demand for the company’s products in Europe, Asia, and for turnkey systems in the United States. Supply to SPI begins immediately.

“We are excited about our agreement with JA Solar. Their products are known for quality and performance and we are very fortunate to be able to integrate them into our own,” said Steve Kircher, CEO Solar Power, Inc. “This is a true strategic relationship with strong mutual benefit. It will allow us to leverage our vertical integration business model through a significant amount of supply and we will be able to offer competitive pricing that we believe is unprecedented,” Mr. Kircher added. “It also provides our SPI commercial operations and our growing Yes! Solar SolutionsTM franchise network with strong advantages in cost of installation and will have a significant positive effect on our competitive position relative to international sales,” Mr. Kircher concluded.

The agreement provides SPI with immediate supply of high-quality cells to meet anticipated production requirements of the company’s family of solar modules during 2009. “We are happy to be providing Solar Power, Inc. with cells for their high-quality PV modules,” said Mr. Samuel Yang, CEO of JA Solar Holding Co., Ltd. “This agreement represents a strategic alliance between our company and one of the leading solar solution providers in the world today. Through SPI we will be able to expand sales of our cells and gain deeper penetration into the U.S. market.”

ABOUT JA SOLAR HOLDINGS CO., LTD.

Based in Hebei, China, JA Solar Holdings Co., Ltd. is a manufacturer of high- performance solar cells. The company sells its products to solar module manufacturers who assemble and integrate its solar cells into modules and systems that convert sunlight into electricity.

PACIFIC ETHANOL INCORPORATED (NASDAQ: PEIX)
"Up 29.79% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/PEIX.php

Pacific Ethanol is the largest West Coast-based marketer and producer of ethanol. Pacific Ethanol has ethanol plants in Madera, California; Boardman, Oregon; and Burley, Idaho and has an additional plant under construction in Stockton, California. Pacific Ethanol also owns a 42% interest in Front Range Energy, LLC which owns an ethanol plant in Windsor, Colorado. Central to Pacific Ethanol's growth strategy is its destination business model, whereby each respective ethanol plant achieves lower process and transportation costs by servicing local markets for both fuel and feed. Pacific Ethanol's goal is to achieve 220 million gallons per year of ethanol production capacity in 2008 and to increase total production capacity to 420 million gallons per year in 2010. In addition, Pacific Ethanol is working to identify and develop other renewable fuel technologies, such as cellulose-based ethanol production and bio-diesel.

PEIX News:

November 17 - Pacific Ethanol, Inc. Announces Adjustment to Its Third Quarter 2008 Financial Results

Pacific Ethanol, Inc. (Nasdaq: PEIX), the leading West Coast-based marketer and producer of ethanol, announced an adjustment to its previously reported financial results for the quarter ended September 30, 2008.

The Company previously reported a non-cash asset impairment charge of $26.6 million related to its suspended Imperial Valley ethanol plant construction project, which represented $43.8 million in property and equipment less $17.2 million in construction-related liabilities. The Company increased its impairment charge by $14.3 million to a total of $40.9 million. The increase represents impairment on the gross amount of $43.8 million in property and equipment less estimated future undiscounted cash flows. This increase will result in future non-cash gains to the extent the Company is discharged from its construction-related liabilities.

The Company's independent registered public accounting firm has completed its review of the Company's financial statements for the period and the Company expects to file its Form 10-Q for the period on November 17, 2008.

The Company's updated Consolidated Statements of Operations and Balance Sheets are set forth below.

ONCOGENEX PHARMA INCORPORATED (NASDAQ: OGXI)
"Up 13.66% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/OGXI.php

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of specific proteins associated with treatment resistance; OGX-427 and SN2310 are in Phase 1 clinical development; and CSP9222 and OGX-225 are currently in pre-clinical development.

OGXI News:

December 3 - OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study

* First-line trial currently shows median overall survival of 27.5 months for OGX-011 in combination with docetaxel and prednisone and a 16.9 months overall survival for docetaxel and prednisone alone.

* Achievement of survival benefit milestone results in release of all remaining escrowed shares of OGXI.

OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI) announced positive survival results from a randomized Phase 2 clinical trial of OGX-011 in combination with docetaxel and prednisone ("the OGX-011 arm") compared to docetaxel and prednisone alone ("the control arm") for first-line treatment of metastatic castrate resistant prostate cancer. The current 10.6 month median overall survival advantage observed in the OGX-011 arm represents an increase over the median survival observed in the control arm. Docetaxel was approved by the FDA based on a survival advantage of 2.4 months over mitoxantrone.

Based on the median overall survival advantage, the Board of Directors of OncoGenex Pharmaceuticals has approved the release of all of the remaining shares held in escrow pursuant to agreements related to Sonus Pharmaceuticals' merger with OncoGenex Technologies described in its Proxy Statement filed with the SEC on July 3, 2008. The escrow agreements provided for the release of 50% of the original number of shares held in escrow following the demonstration of at least a two-month improvement in survival in the OGX-011 arm as compared to the control arm. All milestone shares have now been released from escrow; as of December 3, 2008 there are 5,513,643 shares outstanding.

The trial was conducted and data were analyzed by the National Cancer Institute of Canada, Clinical Trials Group and was supported by a grant from the NCI-Canada with funding from the Canadian Cancer Society. Previous results regarding the primary endpoint analysis (PSA response) were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 2, 2007.

The study randomized 82 patients with metastatic or locally recurring prostate cancer refractory to hormone therapy. The median survival was 27.5 months for the patients in the OGX-011 arm and 16.9 months for those in the control arm. Results currently indicate that patients in the OGX-011 arm have a death rate approximately 40% lower than patients in the control arm. The current results are based on study data with a median follow-up of approximately 30 months for both arms. Additional survival updates are needed before a mature median survival for the OGX-011 arm can be reported. Based on the current results, OncoGenex has calculated that the final median survival for patients in the OGX-011 arm can not be lower than 22.7 months.

An abstract presenting the mature results is planned to be submitted to the American Society of Clinical Oncology (ASCO) meeting.

AIR TRANSPORT SERVICES GROUP (NASDAQ: ATSG)
"Up 3.35% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/ATSG.php

ATSG is a leading provider of air cargo transportation and related services to domestic and foreign air carriers and other companies that outsource their air cargo lift requirements. Through five principal subsidiaries, including three airlines with separate and distinct U.S. FAA Part 121 Air Carrier certificates, ATSG also provides aircraft leasing, aircraft maintenance services, airport ground services, fuel management, specialized transportation management, and air charter brokerage services. ATSG’s subsidiaries include ABX Air, Inc., Air Transport International, LLC, Capital Cargo International Airlines, Inc., Cargo Aircraft Management, Inc., and LGSTX Services, Inc.

ATSG News:

December 12 - ATSG Receives Notice of DHL Service Reductions

Air Transport Services Group, Inc. (Nasdaq: ATSG), announced that its subsidiary ABX Air has been notified that DHL, its principal customer, will discontinue a substantial portion of its U.S.-based domestic express package operations effective January 4, 2009.

ATSG said that DHL intends to close its sorting operations at its U.S. regional hubs, and all domestic daytime package sorting operations except a Sunday day sort operation on that date. Night-time sorting operations will continue in Wilmington.

The closure of these operations will result in the reduction of approximately 1,900 ABX Air positions, including about 1,000 positions in Wilmington, Ohio. The reductions will affect every department of the company. Notifications to affected employees will begin next week.

DHL also notified ABX Air that it will no longer require the use of ABX Air’s DC-9 aircraft after January 2009.

“We have known that this day was coming since DHL announced on November 10 that it would pull out of the U.S. domestic express package market, but it is still a very difficult time for our loyal ABX Air employees who have worked very hard for DHL and its customers,” said Joe Hete, President & CEO of Air Transport Services Group. “Despite this action, however, ABX Air is still in the cargo airline business. DHL has indicated that it wants ABX Air to continue operating most of our Boeing 767 aircraft currently flying under the DHL contract, at least through June 2009. ABX Air also will continue to operate our other cargo aircraft for our charter and ACMI customers.”